1 Recommendations

1.1 Edoxaban is recommended, within its marketing authorisation, as an option for preventing stroke and systemic embolism in adults with non‑valvular atrial fibrillation with one or more risk factors, including:

  • congestive heart failure

  • hypertension

  • diabetes

  • prior stroke or transient ischaemic attack

  • age 75 years or older.

1.2 Decide whether to start treatment with edoxaban after an informed discussion with the person about its risks and benefits compared with warfarin, apixaban, dabigatran etexilate and rivaroxaban. For people taking warfarin, consider the potential risks and benefits of switching to edoxaban taking into account their level of international normalised ratio (INR) control.

  • National Institute for Health and Care Excellence (NICE)